

European Medicines Agency
EU Clinical Trials Register
Domenico Scarlattilaan 6
1083 HS Amsterdam

Date 11 May 2022

Subject EudraCT 2017-002738-22

DexaDays-2 study: Double blind placebo controlled randomized intervention study to validate the beneficial effect of hydrocortisone on dexamethasone-induced neurobehavioral side effects in pediatric acute lymphoblastic leukemia.

Princess Máxima Center for
pediatric oncology

Visiting address
Heidelberglaan 25
3584 CS Utrecht

Postal address
P.O. Box 113
3720 AC Bilthoven

T 088 972 72 72
F 088 972 50 09

CoC Utrecht 54 32 79 46
prinsesmaximacentrum.nl

Click or type (header and footer
view) to add colon text.

The *DexaDays-2* study started in 2018 and the last patient last visit was on 27 March 2021. We included 52 patients in our randomized controlled trial, as anticipated based on our power calculation.

The analyses of our data are finalized, however the results of our study have not been posted to EudraCT thus far. This is due to the fact that the results have a great clinical implication and are therefore still under embargo in our center until the implementation process is complete.

We will upload our results as a full data set as soon as the embargo has been lifted and our main results are published.

With kind regards,



Prof. dr. M.M. van den Heuvel-Eibrink
Principal Investigator